Jpmorgan Chase & CO Aclaris Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 498,721 shares of ACRS stock, worth $952,557. This represents 0.0% of its overall portfolio holdings.

Number of Shares
498,721
Previous 88,320 464.68%
Holding current value
$952,557
Previous $219,000 248.4%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$1.53 - $2.6 $627,913 - $1.07 Million
410,401 Added 464.68%
498,721 $763,000
Q4 2024

Feb 12, 2025
BUY
$1.15 - $4.59 $91,820 - $366,483
79,844 Added 942.0%
88,320 $219,000
Q3 2024

Dec 26, 2024
SELL
$1.12 - $1.4 $479 - $599
-428 Reduced 4.81%
8,476 $9,000
Q3 2024

Nov 08, 2024
SELL
$1.12 - $1.4 $479 - $599
-428 Reduced 4.81%
8,476 $9,000
Q2 2024

Dec 26, 2024
BUY
$1.01 - $1.36 $432 - $582
428 Added 5.05%
8,904 $9,000
Q2 2024

Aug 12, 2024
SELL
$1.01 - $1.36 $61,371 - $82,639
-60,764 Reduced 87.22%
8,904 $9,000
Q1 2024

Dec 26, 2024
BUY
$0.92 - $1.44 $56,296 - $88,116
61,192 Added 721.94%
69,668 $86,000
Q1 2024

May 10, 2024
BUY
$0.92 - $1.44 $87 - $136
95 Added 0.14%
69,668 $86,000
Q4 2023

Dec 26, 2024
BUY
$0.64 - $6.49 $39,102 - $396,519
61,097 Added 720.82%
69,573 $73,000
Q4 2023

Feb 12, 2024
SELL
$0.64 - $6.49 $211,678 - $2.15 Million
-330,748 Reduced 82.62%
69,573 $73,000
Q3 2023

Nov 14, 2023
SELL
$6.56 - $10.95 $174,745 - $291,686
-26,638 Reduced 6.24%
400,321 $2.74 Million
Q2 2023

Aug 11, 2023
SELL
$7.89 - $10.64 $17,421 - $23,493
-2,208 Reduced 0.51%
426,959 $4.43 Million
Q1 2023

May 18, 2023
BUY
$7.07 - $17.95 $527,683 - $1.34 Million
74,637 Added 21.05%
429,167 $3.47 Million
Q1 2023

May 11, 2023
SELL
$7.07 - $17.95 $517,029 - $1.31 Million
-73,130 Reduced 17.1%
354,530 $2.87 Million
Q4 2022

Feb 13, 2023
SELL
$14.33 - $18.37 $362,620 - $464,852
-25,305 Reduced 5.59%
427,660 $6.74 Million
Q3 2022

Nov 14, 2022
SELL
$13.07 - $18.22 $112,807 - $157,256
-8,631 Reduced 1.87%
452,965 $7.13 Million
Q2 2022

Aug 11, 2022
BUY
$10.16 - $17.08 $4.24 Million - $7.12 Million
416,946 Added 933.81%
461,596 $6.44 Million
Q1 2022

May 11, 2022
BUY
$9.74 - $17.92 $72,543 - $133,468
7,448 Added 20.02%
44,650 $770,000
Q4 2021

Feb 10, 2022
BUY
$12.27 - $18.49 $90,503 - $136,382
7,376 Added 24.73%
37,202 $541,000
Q3 2021

Nov 12, 2021
BUY
$13.38 - $18.8 $399,071 - $560,728
29,826 New
29,826 $536,000

Others Institutions Holding ACRS

# of Institutions
98
Shares Held
87.6M
Call Options Held
0
Put Options Held
0
View Full List

About Aclaris Therapeutics, Inc.

ACRS Quotes by TradingView
  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $127M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email